A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
Study for subjects 40 to 65 years-old with a diagnosis of moderate to severe COPD. Aclidinium
bromide 400 mcg 2x a day will be given as an active comparator.